Efficacy, safety and patient reported outcomes in patients with active relapsing multiple sclerosis treated with ocrelizumab: Final results from the PRO-MSACTIVE study

•PRO-MSACTIVE evaluated ocrelizumab in patients with active RMS.•This phase IV study tended to mimic current clinical practice.•Disease activity was assessed by clinical and/or imaging features.•Efficacy and safety profile of ocrelizumab is confirmed in a pragmatic setting.•PRO data allowed a better understanding of MS impact on patients’ lives.